Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago. These ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through ...

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada, Aug. 6, 2025 /CNW/ — ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, following the Company’s receipt of an order ...